These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32824580)

  • 1. C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
    Riedl JM; Barth DA; Brueckl WM; Zeitler G; Foris V; Mollnar S; Stotz M; Rossmann CH; Terbuch A; Balic M; Niedrist T; Bertsch T; Stoeger H; Pichler M; Olschewski H; Absenger G; Ficker JH; Gerger A; Posch F
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.
    Lang D; Brauner A; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Kaiser B; Greil R; Lamprecht B
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.
    Naqash AR; McCallen JD; Mi E; Iivanainen S; Marie MA; Gramenitskaya D; Clark J; Koivunen JP; Macherla S; Jonnalagadda S; Polsani S; Jiwani RA; Hafiz M; Muzaffar M; Brunetti L; Stroud CRG; Walker PR; Wang K; Chung Y; Ruppin E; Lee SH; Yang LV; Pinato DJ; Lee JS; Cortellini A
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline C-reactive protein predicts efficacy of the first-line immune checkpoint inhibitors plus chemotherapy in advanced lung squamous cell carcinoma: a retrospective, multicenter study.
    Zheng X; Zhang L; Wu L; Zhao J; Sun J; Fang Y; Zhou J; Chu Q; Shen Y; Yang Z; Chen L; Huang M; Lin X; Liu Z; Shen P; Wang Z; Wang X; Wang H; Han Z; Liu A; Zhang H; Ye F; Gao W; Wu F; Song Z; Chen S; Zhou C; Wang Q; Xu C; Huang D; Zheng X; Miao Q; Jiang K; Xu Y; Wu S; Wang H; Zhang Q; Yang S; Li Y; Chen S; Lin G
    BMC Cancer; 2023 Dec; 23(1):1244. PubMed ID: 38104105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
    Barth DA; Moik F; Steinlechner S; Posch F; Mayer MC; Sandner AM; Berton F; Schlintl V; Koch L; John N; Wurm R; Pichler M; Bauernhofer T; Reimann P; Wohlkönig C; Richtig E; Winder T; Preusser M; Jost PJ; Ay C; Gerger A; Terbuch A; Riedl JM
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38097343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
    Klümper N; Saal J; Berner F; Lichtensteiger C; Wyss N; Heine A; Bauernfeind FG; Ellinger J; Brossart P; Diem S; Schmid S; Joerger M; Frueh M; Ritter M; Hölzel M; Flatz L; Bald T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35292517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy.
    Öjlert ÅK; Nebdal D; Lund-Iversen M; Åstrøm Ellefsen R; Brustugun OT; Gran JM; Halvorsen AR; Helland Å
    Acta Oncol; 2021 Feb; 60(2):149-156. PubMed ID: 33356733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma.
    Klümper N; Sikic D; Saal J; Büttner T; Goldschmidt F; Jarczyk J; Becker P; Zeuschner P; Weinke M; Kalogirou C; Breyer J; Burger M; Nuhn P; Tully K; Roghmann F; Bolenz C; Zengerling F; Wirtz RM; Muders M; Kristiansen G; Bald T; Ellinger J; Wullich B; Hölzel M; Hartmann A; Erben P; Ritter M; Eckstein M
    Eur J Cancer; 2022 May; 167():13-22. PubMed ID: 35366569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
    Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
    Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer.
    Wei Y; Xu J; Huang X; Xie S; Lin P; Wang C; Guo Y; Zou S; Zhao Z; Wen W; Song Y; Bao Z; Zhang L; Liu W; Kong W; Wang W; He B; Zhang S; Zhou C; Chen Y; Yu Z
    J Thorac Dis; 2023 Apr; 15(4):1892-1900. PubMed ID: 37197527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 15. The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
    Han CL; Meng GX; Ding ZN; Dong ZR; Chen ZQ; Hong JG; Yan LJ; Liu H; Tian BW; Yang LS; Xue JS; Li T
    Front Immunol; 2022; 13():827788. PubMed ID: 35211122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors.
    Iivanainen S; Ahvonen J; Knuuttila A; Tiainen S; Koivunen JP
    ESMO Open; 2019; 4(4):e000531. PubMed ID: 31555483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib.
    Fiala O; Pesek M; Finek J; Topolcan O; Racek J; Minarik M; Benesova L; Bortlicek Z; Poprach A; Buchler T
    Tumour Biol; 2015 Dec; 36(12):9215-22. PubMed ID: 26088452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Wang H; Zhou F; Qiao M; Li X; Zhao C; Cheng L; Chen X; Zhou C
    Front Oncol; 2021; 11():671874. PubMed ID: 34367957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin.
    Qiu Y; Jiang J; Zhang M; Qin Y
    Oncol Lett; 2019 Jul; 18(1):161-168. PubMed ID: 31289485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
    Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
    BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.